XORTX Therapeutics Inc. has provided an update on the timing for closing its planned acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems Limited, an Australian company listed on the ASX. Vectus is currently awaiting clarification from the ASX regarding whether shareholder approval is required for the sale of the VB4-P5 intellectual property. According to the binding term sheet between XORTX and Vectus, closing is scheduled to occur no later than 90 days after signing, which is January 13, 2026. Both companies remain committed to finalizing the acquisition and will provide additional updates once there is clarity on the ASX approval process.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XORTX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9618770) on December 31, 2025, and is solely responsible for the information contained therein.